HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.

Abstract
Melanomas display poor response rates to adjuvant therapies because of their intrinsic resistance to proapoptotic stimuli. This study indicates that such resistance can be overcome, at least partly, through the targeting of eEF1A elongation factor with narciclasine, an Amaryllidaceae isocarbostyril controlling plant growth. Narciclasine displays IC(50) growth inhibitory values between 30-100 nM in melanoma cell lines, irrespective of their levels of resistance to proapoptotic stimuli. Normal noncancerous cell lines are much less affected. At nontoxic doses, narciclasine also significantly improves (P=0.004) the survival of mice bearing metastatic apoptosis-resistant melanoma xenografts in their brain. The eEF1A targeting with narciclasine (50 nM) leads to 1) marked actin cytoskeleton disorganization, resulting in cytokinesis impairment, and 2) protein synthesis impairment (elongation and initiation steps), whereas apoptosis is induced at higher doses only (≥200 nM). In addition to molecular docking validation and identification of potential binding sites, we biochemically confirmed that narciclasine directly binds to human recombinant and yeast-purified eEF1A in a nanomolar range, but not to actin or elongation factor 2, and that 5 nM narciclasine is sufficient to impair eEF1A-related actin bundling activity. eEF1A is thus a potential target to combat melanomas regardless of their apoptosis-sensitivity, and this finding reconciles the pleiotropic cytostatic of narciclasine.
AuthorsGwendoline Van Goietsenoven, Jenna Hutton, Jean-Paul Becker, Benjamin Lallemand, Francis Robert, Florence Lefranc, Christine Pirker, Guy Vandenbussche, Pierre Van Antwerpen, Antonio Evidente, Walter Berger, Martine Prévost, Jerry Pelletier, Robert Kiss, Terri Goss Kinzy, Alexander Kornienko, Véronique Mathieu
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J) Vol. 24 Issue 11 Pg. 4575-84 (Nov 2010) ISSN: 1530-6860 [Electronic] United States
PMID20643906 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amaryllidaceae Alkaloids
  • Antineoplastic Agents
  • EEF1A1 protein, human
  • Hydroxyquinolines
  • Peptide Elongation Factor 1
  • Phenanthridines
  • Quinolones
  • narciclasine
  • carbostyril
Topics
  • Amaryllidaceae Alkaloids (pharmacology)
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Binding Sites
  • Cell Line, Tumor
  • Cytoskeleton (drug effects)
  • Drug Delivery Systems
  • Gene Expression Regulation (drug effects)
  • Humans
  • Hydroxyquinolines (pharmacology)
  • Liliaceae (chemistry)
  • Melanoma
  • Mice
  • Models, Molecular
  • Peptide Elongation Factor 1 (metabolism)
  • Phenanthridines (pharmacology)
  • Quinolones (pharmacology)
  • Saccharomyces cerevisiae (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: